Selected article for: "clinical trial and DM diabetes mellitus"
Author: Al-kuraishy, Hayder M.; Al-Gareeb, Ali I.; Alblihed, M.; Guerreiro, Susana G.; Cruz-Martins, Natália; Batiha, Gaber El-Saber
Title: COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus
  • Cord-id: adfqopjg
  • Document date: 2021_5_20
    • ID: adfqopjg
    Snippet: Coronavirus disease 2019 (COVID-19), triggered by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), may lead to extrapulmonary manifestations like diabetes mellitus (DM) and hyperglycemia, both predicting a poor prognosis and an increased risk of death. SARS-CoV-2 infects the pancreas through angiotensin-converting enzyme 2 (ACE2), where it is highly expressed compared to other organs, leading to pancreatic damage with subsequent impairment of insulin secretion and development of
    Document: Coronavirus disease 2019 (COVID-19), triggered by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), may lead to extrapulmonary manifestations like diabetes mellitus (DM) and hyperglycemia, both predicting a poor prognosis and an increased risk of death. SARS-CoV-2 infects the pancreas through angiotensin-converting enzyme 2 (ACE2), where it is highly expressed compared to other organs, leading to pancreatic damage with subsequent impairment of insulin secretion and development of hyperglycemia even in non-DM patients. Thus, this review aims to provide an overview of the potential link between COVID-19 and hyperglycemia as a risk factor for DM development in relation to DM pharmacotherapy. For that, a systematic search was done in the database of MEDLINE through Scopus, Web of Science, PubMed, Embase, China National Knowledge Infrastructure (CNKI), China Biology Medicine (CBM), and Wanfang Data. Data obtained underline that SARS-CoV-2 infection in DM patients is more severe and associated with poor clinical outcomes due to preexistence of comorbidities and inflammation disorders. SARS-CoV-2 infection impairs glucose homeostasis and metabolism in DM and non-DM patients due to cytokine storm (CS) development, downregulation of ACE2, and direct injury of pancreatic β-cells. Therefore, the potent anti-inflammatory effect of diabetic pharmacotherapies such as metformin, pioglitazone, sodium-glucose co-transporter-2 inhibitors (SGLT2Is), and dipeptidyl peptidase-4 (DPP4) inhibitors may mitigate COVID-19 severity. In addition, some antidiabetic agents and also insulin may reduce SARS-CoV-2 infectivity and severity through the modulation of the ACE2 receptor expression. The findings presented here illustrate that insulin therapy might seem as more appropriate than other anti-DM pharmacotherapies in the management of COVID-19 patients with DM due to low risk of uncontrolled hyperglycemia and diabetic ketoacidosis (DKA). From these findings, we could not give the final conclusion about the efficacy of diabetic pharmacotherapy in COVID-19; thus, clinical trial and prospective studies are warranted to confirm this finding and concern.

    Search related documents:
    Co phrase search for related documents
    • abnormal cytokine response and acute sars cov respiratory syndrome coronavirus: 1
    • abnormal expression and acute ards respiratory distress syndrome: 1
    • abnormal expression and acute disease: 1
    • abnormal expression and acute kidney injury: 1
    • abnormal expression and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • ace inhibitor and acute cardiac injury: 1, 2
    • ace inhibitor and acute disease: 1, 2, 3, 4
    • ace inhibitor and acute infection: 1, 2, 3, 4, 5
    • ace inhibitor and acute kidney injury: 1, 2, 3, 4
    • ace inhibitor and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • ace inhibitor statin and acute sars cov respiratory syndrome coronavirus: 1
    • activation platelet aggregation and acute disease: 1
    • activation platelet aggregation and acute infection: 1, 2
    • activation platelet aggregation and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • activation platelet aggregation and acute viral infection: 1